Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
Abstract Background The therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive in breast cancer susceptibility genes (BRCA)1/2-mutat...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13048-023-01283-2 |
| _version_ | 1797647205425741824 |
|---|---|
| author | Yana Ma Jiale Liu Ning Li Hualei Bu Yongwen Huang Chengjuan Jin Hao Wen Shuai Feng Hui Zhang Xiaorong Yang Beihua Kong Lingying Wu Kun Song |
| author_facet | Yana Ma Jiale Liu Ning Li Hualei Bu Yongwen Huang Chengjuan Jin Hao Wen Shuai Feng Hui Zhang Xiaorong Yang Beihua Kong Lingying Wu Kun Song |
| author_sort | Yana Ma |
| collection | DOAJ |
| description | Abstract Background The therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive in breast cancer susceptibility genes (BRCA)1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. Methods BRCA1/2-mutated patients with secondary platinum-sensitive relapse included in this study did not receive any maintenance regimen after first- and second-line platinum-based chemotherapy, and the secondary platinum-free interval (PFI) was more than 6 months. Patients in study group were treated with PARPi monotherapy until disease progression, and patients in control group were treated with platinum-based chemotherapy without restriction. Progression-free survival (PFS) was defined as the time from third-line therapy to disease progression or death, PFS2 was defined as the time from platinum-based chemotherapy after PARPi resistance to next subsequent therapy or death. Post-recurrence survival (PRS) refers to the survival time after secondary platinum-sensitive relapse. Results A total of 119 patients were retrospectively analyzed, including 71 (59.7%) in study group and 48 (40.3%) in control group. The objective response rate (ORR: 77.5% vs. 80.0%, p=0.766) and PFS (median: 11.2 vs. 11.0 months, p=0.962) were comparable. The benefit of subsequent platinum-based chemotherapy after PARPi resistance was more pronounced in patients with PARPi treatment for more than 12 months (median PFS2: 8.6 vs. 4.3 months, p=0.040). PARPi monotherapy had no adverse effect on PRS compared with platinum-based chemotherapy (median PRS:41.2 vs. 42.8 months, p=0.323). Compared to patients in control group who had never received PARPi, PARPi monotherapy (median PRS: 41.2 vs. 33.7 months, p=0.019) and post-line treatment with PARPi in the control group (median PRS: 48.1 vs. 33.7 months, p=0.002) could prolong PRS for patients with secondary platinum-sensitive relapse. Conclusions PARPi monotherapy was similar to platinum-based chemotherapy for BRCA1/2-mutated ovarian cancer patients with secondary platinum-sensitive recurrence, and could improve prognosis. |
| first_indexed | 2024-03-11T15:13:56Z |
| format | Article |
| id | doaj.art-8e7ef6a125174ca0be522d3c813836b7 |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-03-11T15:13:56Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-8e7ef6a125174ca0be522d3c813836b72023-10-29T12:32:22ZengBMCJournal of Ovarian Research1757-22152023-10-011611910.1186/s13048-023-01283-2Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapseYana Ma0Jiale Liu1Ning Li2Hualei Bu3Yongwen Huang4Chengjuan Jin5Hao Wen6Shuai Feng7Hui Zhang8Xiaorong Yang9Beihua Kong10Lingying Wu11Kun Song12Department of Obstetrics and Gynecology, Qilu Hospital of Shandong UniversityDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong UniversityDepartment of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong UniversityGynecologic Department, Sun Yat-sen University Cancer CenterDepartment of Obstetrics and Gynecology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong UniversityDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer CenterGynecological Oncology Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical SciencesDepartment of Gynecology, The Fourth Hospital of Hebei Medical UniversityClinical Epidemiology Unit, Qilu Hospital of Shandong UniversityDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong UniversityDepartment of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong UniversityAbstract Background The therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive in breast cancer susceptibility genes (BRCA)1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse. Methods BRCA1/2-mutated patients with secondary platinum-sensitive relapse included in this study did not receive any maintenance regimen after first- and second-line platinum-based chemotherapy, and the secondary platinum-free interval (PFI) was more than 6 months. Patients in study group were treated with PARPi monotherapy until disease progression, and patients in control group were treated with platinum-based chemotherapy without restriction. Progression-free survival (PFS) was defined as the time from third-line therapy to disease progression or death, PFS2 was defined as the time from platinum-based chemotherapy after PARPi resistance to next subsequent therapy or death. Post-recurrence survival (PRS) refers to the survival time after secondary platinum-sensitive relapse. Results A total of 119 patients were retrospectively analyzed, including 71 (59.7%) in study group and 48 (40.3%) in control group. The objective response rate (ORR: 77.5% vs. 80.0%, p=0.766) and PFS (median: 11.2 vs. 11.0 months, p=0.962) were comparable. The benefit of subsequent platinum-based chemotherapy after PARPi resistance was more pronounced in patients with PARPi treatment for more than 12 months (median PFS2: 8.6 vs. 4.3 months, p=0.040). PARPi monotherapy had no adverse effect on PRS compared with platinum-based chemotherapy (median PRS:41.2 vs. 42.8 months, p=0.323). Compared to patients in control group who had never received PARPi, PARPi monotherapy (median PRS: 41.2 vs. 33.7 months, p=0.019) and post-line treatment with PARPi in the control group (median PRS: 48.1 vs. 33.7 months, p=0.002) could prolong PRS for patients with secondary platinum-sensitive relapse. Conclusions PARPi monotherapy was similar to platinum-based chemotherapy for BRCA1/2-mutated ovarian cancer patients with secondary platinum-sensitive recurrence, and could improve prognosis.https://doi.org/10.1186/s13048-023-01283-2PARPi monotherapyPlatinum-sensitive recurrenceBRCA1/2 mutationPost-recurrence survival |
| spellingShingle | Yana Ma Jiale Liu Ning Li Hualei Bu Yongwen Huang Chengjuan Jin Hao Wen Shuai Feng Hui Zhang Xiaorong Yang Beihua Kong Lingying Wu Kun Song Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse Journal of Ovarian Research PARPi monotherapy Platinum-sensitive recurrence BRCA1/2 mutation Post-recurrence survival |
| title | Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse |
| title_full | Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse |
| title_fullStr | Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse |
| title_full_unstemmed | Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse |
| title_short | Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse |
| title_sort | efficacy of poly adp ribose polymerase inhibitors monotherapy and the impact to subsequent platinum based chemotherapy in breast cancer susceptibility genes1 2 mutated ovarian cancer patients with secondary platinum sensitive relapse |
| topic | PARPi monotherapy Platinum-sensitive recurrence BRCA1/2 mutation Post-recurrence survival |
| url | https://doi.org/10.1186/s13048-023-01283-2 |
| work_keys_str_mv | AT yanama efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT jialeliu efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT ningli efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT hualeibu efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT yongwenhuang efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT chengjuanjin efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT haowen efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT shuaifeng efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT huizhang efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT xiaorongyang efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT beihuakong efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT lingyingwu efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse AT kunsong efficacyofpolyadpribosepolymeraseinhibitorsmonotherapyandtheimpacttosubsequentplatinumbasedchemotherapyinbreastcancersusceptibilitygenes12mutatedovariancancerpatientswithsecondaryplatinumsensitiverelapse |